4-butyrolactone has been researched along with rosiglitazone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cooley, MA; Rolph, MS; Whittall, C | 1 |
| Bai, K; Fan, C; He, J; Hong, B; Le, Q; Niu, S; Tang, C; Xiao, M | 1 |
2 other study(ies) available for 4-butyrolactone and rosiglitazone
| Article | Year |
|---|---|
Pseudomonas signal molecule 3-oxo-C12-homoserine lactone interferes with binding of rosiglitazone to human PPARgamma.
Topics: 4-Butyrolactone; Anti-Inflammatory Agents; Homoserine; Humans; PPAR gamma; Protein Binding; Pseudomonas aeruginosa; Rosiglitazone; Thiazolidinediones | 2010 |
Synthesis and Biological Evaluation of Analogues of Butyrolactone I as PTP1B Inhibitors.
Topics: 4-Butyrolactone; Cell Line; Cell Proliferation; Glucose; Humans; Hypoglycemic Agents; Insulin; Molecular Structure; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Rosiglitazone | 2020 |